---
title: "Sinopharm Accord: Expected net profit in 2024 to decline by 52.48%-64.92% year-on-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225338539.md"
description: "Sinopharm Accord expects its net profit in 2024 to decline by 52.48%-64.92% year-on-year, with a net profit attributable to shareholders of the listed company ranging from 561 million yuan to 760 million yuan. The net profit after deducting non-recurring gains and losses is expected to be between 497 million yuan and 696 million yuan, with basic earnings per share ranging from 1.01 yuan/share to 1.37 yuan/share. The decline in performance is mainly due to the impact of changes in industry policies and intensified market competition in the retail sector, with an estimated provision for goodwill and intangible asset impairment of approximately 876 million yuan to 1.07 billion yuan"
datetime: "2025-01-17T11:04:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225338539.md)
  - [en](https://longbridge.com/en/news/225338539.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225338539.md)
generator: "portal-rs"
---

# Sinopharm Accord: Expected net profit in 2024 to decline by 52.48%-64.92% year-on-year

Sinopharm Accord announced that it expects the net profit attributable to shareholders of the listed company for 2024 to be between 561 million and 760 million yuan, a decrease of 52.48%-64.92% compared to the same period last year. The net profit after deducting non-recurring gains and losses is expected to be between 497 million and 696 million yuan, a decrease of 54.59%-67.58% compared to the same period last year. The basic earnings per share are expected to be between 1.01 yuan/share and 1.37 yuan/share. The decline in performance is mainly due to the impact of changes in industry policies and intensified market competition in the retail sector. It is expected to recognize an impairment provision for goodwill and intangible assets of approximately 876 million to 1.07 billion yuan, which is expected to reduce the net profit attributable to shareholders of the listed company during the reporting period by 505 million to 618 million yuan

### Related Stocks

- [000028.CN](https://longbridge.com/en/quote/000028.CN.md)
- [200028.CN](https://longbridge.com/en/quote/200028.CN.md)
- [06110.HK](https://longbridge.com/en/quote/06110.HK.md)
- [01929.HK](https://longbridge.com/en/quote/01929.HK.md)
- [000001.CN](https://longbridge.com/en/quote/000001.CN.md)

## Related News & Research

- [REG - NextEnergy Solar Fnd - Result of AGM](https://longbridge.com/en/news/298041368.md)
- [RUBBER-Japan rubber futures ease as oil prices slip, yen firms](https://longbridge.com/en/news/297846575.md)
- [Hartalega publishes presentation for 20th AGM](https://longbridge.com/en/news/297878053.md)
- [Asker Healthcare agrees to buy Poland medical equipment distributor Labo Clinic](https://longbridge.com/en/news/297879779.md)
- [JIC Venture Growth Investments buys minority stake in SiccaNova Therapeutics via Fund 2](https://longbridge.com/en/news/297855259.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**